BPC-157: The Complete Researcher's Guide to Body Protection Compound
Share
BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide consisting of 15 amino acids, derived from a partial sequence of human gastric juice protein. It is one of the most extensively studied peptides in preclinical research, with a broad range of documented biological activities across tissue repair, gastrointestinal, neurological, and vascular research models.
What Is BPC-157?
BPC-157 is a stable gastric pentadecapeptide — stable meaning it retains activity in human gastric juice, which is the environment from which it was originally isolated. The compound does not occur naturally in isolation but is derived from the sequence of a larger gastric protein.
Key biochemical properties:
- Amino acid count: 15
- Molecular weight: ~1,419 Da
- Sequence: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val
- Form: Lyophilized powder
- Purity (Star Valley Peptides): ≥99% HPLC-verified
- Storage: 2–8°C
Mechanisms of Action
Angiogenesis and VEGF Upregulation
One of the most consistently documented effects of BPC-157 in preclinical models is the upregulation of vascular endothelial growth factor (VEGF) and promotion of angiogenesis — the formation of new blood vessels. This mechanism is central to its observed effects on tissue repair across multiple model types.
Nitric Oxide System Modulation
BPC-157 interacts with the nitric oxide (NO) system, with research demonstrating both NO-dependent and NO-independent pathways. The compound appears to modulate eNOS activity and has shown cytoprotective effects in endothelial cell models.
Growth Hormone Receptor Interaction
Preclinical data suggests BPC-157 may interact with growth hormone receptor pathways, which has implications for its observed effects on tendon and bone repair models.
FAK-paxillin Pathway
Research has identified BPC-157's involvement in the focal adhesion kinase (FAK) and paxillin signaling pathway, which plays a role in cell migration and wound healing processes.
Gastrointestinal Cytoprotection
BPC-157 was originally studied for its cytoprotective effects on the gastrointestinal tract. Preclinical models have demonstrated protective effects against NSAID-induced gastric lesions, inflammatory bowel disease models, and gut-brain axis disruption.
Research Applications
| Research Area | Key Mechanism | Model Type |
|---|---|---|
| Tendon & ligament repair | VEGF upregulation, angiogenesis | Rodent tendon transection models |
| Muscle repair | Satellite cell activation, angiogenesis | In vivo crush injury models |
| Bone healing | GH receptor interaction, angiogenesis | Rodent fracture models |
| GI cytoprotection | NO modulation, mucosal protection | NSAID lesion, IBD models |
| Neurological research | Dopamine system modulation | Rodent CNS models |
| Wound healing | FAK-paxillin, cell migration | Excisional wound models |
| Vascular research | eNOS, angiogenesis | Endothelial cell models |
BPC-157 and TB-500: Why Researchers Combine Them
BPC-157 and TB-500 (Thymosin Beta-4) are frequently studied in combination in tissue repair research. The rationale is mechanistic complementarity:
- BPC-157 drives angiogenesis and local tissue repair signaling
- TB-500 promotes actin polymerization, cell migration, and systemic anti-inflammatory effects
The combination — sometimes referred to as the "Wolverine Stack" in research contexts — targets tissue repair through two distinct but complementary pathways. Star Valley Peptides carries both compounds individually and as the Wolverine Stack.
Storage and Handling Protocol
- Store lyophilized at 2–8°C for active use, −20°C for long-term archiving
- Minimize exposure to moisture and light
- Avoid repeated freeze-thaw cycles — aliquot before freezing
- Reconstitute with Bacteriostatic Water (not included)
- Reconstituted solution: 2–8°C, use within 4 weeks
Star Valley Peptides BPC-157 Specifications
| Specification | Value |
|---|---|
| Purity | ≥99% (HPLC-verified) |
| Endotoxin | <0.1 EU/mg |
| Appearance | White lyophilized powder |
| Manufacturing | ISO-certified conditions |
| Documentation | Certificate of Analysis included |
| Storage | 2–8°C |
| Shipping | Worldwide, discreet packaging |
BPC-157 is available at peptidespro.online. For bulk orders or protocol consultation: 94300791@qq.com
References
- Sikiric, P., Seiwerth, S., Rucman, R., et al. (2013). Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. Current Pharmaceutical Design, 17(16), 1612–1632. PubMed: 21548867
- Chang, C.H., Tsai, W.C., Lin, M.S., Hsu, Y.H., & Pang, J.H. (2011). The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. Journal of Applied Physiology, 110(3), 774–780. PubMed: 21148156
- Sikiric, P., Seiwerth, S., Rucman, R., et al. (2018). Brain-gut Axis and Pentadecapeptide BPC 157: Theoretical and Practical Implications. Current Neuropharmacology, 14(8), 857–865. PubMed: 27012953
- Gwyer, D., Wragg, N.M., & Wilson, S.L. (2019). Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell and Tissue Research, 377, 153–159. PubMed: 31055680
- Sikiric, P., Hahm, K.B., Blagaic, A.B., et al. (2020). Stable Gastric Pentadecapeptide BPC 157, Robert's Stomach Cytoprotection/Adaptive Cytoprotection/Organoprotection, and Selye's Stress Coping Response. Biomedicines, 8(8), 265. PubMed: 32781558
All products sold by Star Valley Peptides are strictly for laboratory and scientific research purposes only. Not intended for human or animal therapeutic use. Not approved by any regulatory authority for clinical application.